ClinicalTrials.gg
RecruitingNCT04807881Updated Oct 29, 2026

Phase Ib Clinical Study of Keynatinib

A Phase 1 interventional study of Keynatinib in Lymphoma, B-Cell, sponsored by Medolution Ltd.. Recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Medolution Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Sep 2020, registered Mar 2021).
  • Started Sep 2020; still recruiting 6 years 1 month later.
Updated Oct 29, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 283 studies in Lymphoma, B-Cell with a site in China — 125 open to participants now, 146 under way, 9 of them phase 3. Lymphoma, B-Cell · China.

Planned enrollment
67th of 273
75 · median 30
Started
2020
with 21 others
Phase 1
124 of 283
57 open now
Primary completion
2032-10
later than 144 of 145 live
Registered
113th of 283
by date

Among the 283 studies in Lymphoma, B-Cell with a site in China, this one is the 67th largest by planned enrollment of the 273 interventional ones that give a count, is one of 22 that started in 2020, is one of 124 in phase 1, reaches primary completion later than 144 of the 145 other live ones, and was the 113th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

125 of the 283 studies in Lymphoma, B-Cell with a site in China are open now. Recruiting first, the newest first:

120 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Lymphoma, B-Cell with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, PK characteristics in subjects with relapsed/refractory B-cell lymphoma. Furthermore, the relationship between the exposure level of Keynatinib and its efficacy and safety, the penetration rate of keynatinib in the Blood-Brain Barrier (BBB) and its PK characteristics in cerebrospinal fluid in R/R-PCNSL patients, the relationship between the BTK receptor occupancy rate and the efficacy are also evaluated.

Read the detailed description

This tiral adopts a multi-center, single-arm, multi-cohort, and open-label design to evaluate the efficacy and safety of keynatinib in patients with relapsed/refractory B-cell lymphoma.

There will be three cohorts in this trial, details as follows: Cohort 1: R/R-PCNSL subjects; Cohort 2: R/R-CLL/SLL subjects; Cohort 3: R/R-MCL subjects.

10-25 subjects will be enrolled in the R/R-PCNSL, R/R-CLL/SLL, and R/R-MCL cohorts, respectively.

03

Conditions studied

  • Lymphoma, B-Cell

Keywords

  • Relapsed/Refractory Primary Central Nervous System Lymphoma
  • Relapsed/Refractory Chronic Lymphoblastic Leukemia
  • Relapsed/Refractory Small Lymphocytic Lymphoma
  • Relapsed/Refractory Mantle Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Unlimited gender, age ≥ 18 years (including critical value)-Cohort 1/2/3;
  2. Voluntarily participate in the study and sign the ICF, follow the trial treatment protocol and interview plan-Cohort 1/2/3;
  3. The subject's disease diagnosis meets all of the following conditions:

    Cohort 1:

    1. Primary central nervous system lymphoma (PCNSL) confirmed by pathology;
    2. For PCNSL, at least treatment must be given to Central Nervous System (CNS) lesions;
    3. Brain Magnatic resonance Imaging (MRI) or Computerized tomography (CT) shows solid lesions of PD;

    Cohort 2:

    1. CLL/SLL diagnosed according to IWCLL 2008 standards;
    2. Refractory or relapsed CLL/SLL that previously received at least first-line systemic treatment. First-line treatment is defined as at least 2 cycles of standard protocol or clinical trial research protocol completed based on current guidelines;
    3. Accord with at least one indication of CLL / SLL that requiring treatment;
    4. There is medical record confirming that it is invalid or Progression Disease occurs after response for the latest treatment;
    5. CT /MRI shows , which is defined as at least one lymph node with a maximum axis of more than 1.5 cm and with 2 measurable vertical dimension;
    6. It is allowed to include the patients with a stable condition involving the central nervous system;

    Cohort 3:

    1. Mantle cell lymphoma diagnosed by histopathology: including that t (11; 14) (q13; q32) positive by cytogenetic test and / or cyclin D1 highly expressed by immunohistochemistry;
    2. Who have been pretreated with > 1 but failed in ≤ 3 different chemotherapies and / or targeted drugs treatment.
    3. There is a medical record confirming that it is invalid or Progression Disease occurs after response for the latest treatment;
    4. CT / MRI shows measurable lesions, which is defined as the longest diameter (of ≥1 lymph node) > 1.5 cm, and 2 vertical diameters is clearly measurable;
    5. It is allowed to include the patients with a stable condition involving the central nervous system;
  4. When screening, the status score of (ECOG) is 0 to 2 points-Cohort 1/2/3;
  5. Estimated survival time ≥ 4 months-Cohort 1/2/3;
  6. Subjects have appropriate organ functions, the main organ functions meet the following criteria:

    1. Blood routine: Neutrophil absolute value ≥ 1.0(in cohort1, 0.75 in cohort 2/3)×109 /L, ≥ 75(in cohort1, 50 in cohort 2/3, 30×109/L are acceptable if CLL patients have bone marrow involvement, transfusion-dependent thrombocytopenia is excluded )×109 /L, ≥ 80 g/L(in cohort1). [No blood transfusion and hematopoietic stimulating factor are used within 21 days (7 days in cohort 2/3) before the first administration-Chort1];
    2. Blood biochemistry: Total (TBIL) ≤ 2 × (unless diagnosed as Gilbert syndrome), (AST) and Alanine aminotransferase (ALT) ≤ 2.5 × ULN; serum creatinine ≤ 2 × ULN or rate ≥ 50 ml / min (calculated according to Cockcroft Gault formula)-Cohort 1/2/3;
    3. Coagulation function: International Standardized Ratio () and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN-Cohort 1/2/3;
  7. Fertile female subjects must agree to use with an annual failure rate of \< 1% or maintain abstinence (avoid heterosexual intercourse) during the study and at least 90 days after the last administration of the study drug. Contraceptive methods with an annual failure rate of \<1% includes bilateral tubal ligation, male sterilization, proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing IUD (intrauterine devices), and copper-containing IUD. Male subjects must be sterilized by vasectomy or barrier contraception, and female partners should use the effective contraceptives as described above. In addition, male subjects are not allowed to donate sperm within 90 days after the last administration-Cohort 1/2/3.

Exclusion criteria

Exclusion Criteria:

  • Cohort 1: R/R-PCNSL

    1. PCNSL is diagnosed as T-cell lymphoma;
    2. Have previously received any of the following treatments:

      1. Chemotherapy, targeted therapy, radiotherapy or antibody based anti-tumor therapy are used within 4 weeks before the first administration or within 5 half-lives (whichever is shorter);
      2. Have previously received the treatment of B Cell Receptor (BCR) inhibitors (such as BTK, phosphoinositide kinase 3 kinase [PI3K] or SYK inhibitors) or BCL-2 inhibitors (such as ABT-199) or Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) or a bispecific antibody drug;
      3. Have received Allogenetic Haematopoietic Stem Cell Transplantation (Allo-) or other organ transplants (except for those who have received ASCT more than six months);
    3. Take ≥ 8 mg dexamethasone or equivalent daily to control lymphoma symptoms;
    4. CNS external beam radiotherapy within 21 days before the first administration;
    5. The systemic , including cyclosporine A, tacrolimus, sirolimus and other drugs, haven't stopped 28 days before the first use of the study drug, or > 5 mg/day of prednisone or its equivalent has been taken for long period;
    6. Have other malignant tumors within 3 years, except for the curable basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of cervix or breast;
    7. Non-hematologic toxicity of the previous anti-tumor treatment has not recovered to ≤ grade 1 (except for hair loss);
    8. Have uncontrollable or severe cardiovascular disease, including:

      1. Congestive heart failure with (NYHA) grade II or higher, unstable angina, myocardial infarction within 6 months before first study drug administration, or arrhythmia requiring treatment during screening, (LVEF) \<50% ;
      2. Primary cardiomyopathy (such as dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, and atypical cardiomyopathy);
      3. prolonged medical history, or the QTc interval of screening period > 470 ms in female, and > 450 ms in male;
      4. Uncontrollable high blood pressure (on the basis of improving life style, with 2 or more antihypertensive drugs (including diuretics) that will be reasonably tolerable and sufficient for more than one month being applied, the blood pressure has not reached to the standard yet, or the blood pressure could only be effectively controlled by taking 4 or more antihypertensive drugs);
    9. Have active bleeding within 2 months before screening or are taking anticoagulant/antiplatelet drugs, or the investigators believe that there is a clear bleeding tendency (such as esophageal varices with bleeding risk, or a locally active ulcer lesions);
    10. Have medical history of deep vein thrombosis or pulmonary embolism;
    11. Have medical history of stroke or intracranial hemorrhage within 6 months before taking the study drug, except for intracranial hemorrhage due to surgical sequelae;
    12. Have clinically significant gastrointestinal abnormalities, which might affect drug intake, transport or absorption (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.);
    13. Have serious or active infection requiring systematic anti infection treatment;
    14. At screening, patients with active uncontrolled infection [such as infection that requiring intravenous antibiotic therapy, (HIV), virus (HBV) or virus (HCV) infection, etc.]; Note: If hepatitis B virus surface antigen (HBsAg) is positive, HBV-DNA \< 1000 cop/ml, and /AST ≤ 2.0 × can be included. HCV infection is defined as HCV-Ab positive.
    15. Have past history of or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe impairment of lung function, etc;
    16. Have undergone major surgery or have not recovered from the invasive operation within 4 weeks before taking the study drug for the first time and are not suitable for the clinical trial according to the judgment of the investigators;
    17. Who is participating in other clinical studies or have participated in other intervention clinical trials within 4 weeks before screening;
    18. Have history of alcohol or drug abuse;
    19. Pregnant or lactating women;
    20. Concomitant administration of drugs with moderate to severe inhibition or strong induction of cytochrome P450
    21. Subjects determined by the investigators to be unsuitable for other reasons;

Cohort 2: R/R-CLL/SLL

  1. Have medical history of prolymphocytic leukemia, known medical history of Richter syndrome or currently suspected Richter transformation (patients with clinical suspicion need to exclude transformation)
  2. Have previously received any of the following treatments:

    1. Chemotherapy, targeted therapy, radiotherapy or antibody-based anti-tumor therapy within 4 weeks or 5 half-lives (whichever is shorter) before the first administration;
    2. Previous treatment with BTK, phosphoinositide kinase 3 kinase [PI3K] or SYK inhibitors or BCL-2 inhibitors (such as ABT-199) or chimeric antigen receptor T cell immunotherapy (CAR-T) or treatment with bispecific antibody drugs;
    3. Patients who received allogeneic hematopoietic stem cell transplantation (Allo-HSCT) or other organ transplantation within the past 6 months;
    4. Patients who received autologous hematopoietic stem cell transplantation within the past 6 months;
  3. Use of systemic within 7 days before the first administration of study drug, or continuous use of prednisone at or above 20 mg/day or equivalent;
  4. Other within 3 years, except for curable basal or squamous cell skin cancer, superficial bladder cancer, and carcinoma in situ of the uterine cervix or breast;
  5. Non-hematologic toxicity of the previous anti-tumor treatment has not recovered to ≤ grade 1 (except for hair loss);
  6. Have uncontrollable or severe cardiovascular disease, including:

    1. Congestive heart failure with New York Heart Association (NYHA) grade II or higher, unstable angina, myocardial infarction within 6 months before first study drug administration, or arrhythmia requiring treatment during screening period, Left Ventricular Ejection Fraction (LVEF) \<50%;
    2. Primary cardiomyopathy (such as dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, and atypical cardiomyopathy);
    3. Clinically significant QTc interval prolonged medical history, or the QTc interval of screening period > 470 ms in female, and > 450 ms in male;
    4. Uncontrollable high blood pressure (on the basis of improving life style, with 2 or more antihypertensive drugs (including diuretics) being applied that will be reasonably tolerable and sufficient for more than one month, the blood pressure has not reached to the standard yet, , or the blood pressure could only be effectively controlled by taking 4 or more antihypertensive drugs);
  7. Have active bleeding within 2 months before screening or is taking anticoagulant/antiplatelet drugs, or the investigators believe that there is a clear bleeding tendency (such as esophageal varices with bleeding risk, or a locally active ulcer lesions);
  8. Active and/or persistent anemia and/or autoimmune thrombocytopenia requiring treatment (e.g., idiopathic thrombocytopenic purpura);
  9. Have medical history of deep vein thrombosis or pulmonary embolism;
  10. Have medical history of stroke or intracranial hemorrhage within 6 months before taking study drug;
  11. Have clinically significant gastrointestinal abnormalities, which might affect drug intake, transport or absorption (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.);
  12. Have active infection requiring systemic anti-infective treatment;
  13. At screening, patients with active uncontrolled infection [such as intravenous infection that requiring antibiotic therapy, human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, etc.]; Note: If hepatitis B virus surface antigen (HBsAg) is positive, HBV-DNA \< 1000 cop/ml, and ALT/AST ≤ 2.0 × ULN can be included. HCV infection is defined as HCV-Ab positive.
  14. Have past history of or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe impairment of lung function, etc;
  15. Have history of alcohol or drug abuse;
  16. Have undergone major surgery or have not recovered from the invasive operation within 4 weeks before taking the study drug for the first time and are not suitable for the clinical trial according to the judgment of the investigators;
  17. Whowill participating in other clinical studies or haveparticipated in other intervention clinical trials within 4 weeks before screening;
  18. Pregnant or lactating women;
  19. Concomitant administration of drugs with moderate to severe inhibition or strong induction of cytochrome P450 CYP3A;
  20. Subjects determined by the investigators to be unsuitable for other reasons;

Cohort 3: R/R-MCL

  1. Havepreviously received any of the following treatments:

    1. Chemotherapy, targeted therapy, radiotherapy or antibody based anti-tumor therapy are used within the first 4 weeks or 5 half-lives (whichever is shorter) before the first administration;
    2. Have previously received the treatment of BTK, phosphoinositide kinase 3 kinase [PI3K] or SYK inhibitors) or BCL-2 inhibitors (such as ABT-199) or Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) or received bispecific antibody drug;
  2. Use of systemic corticosteroids at or above 20 mg/day prednisone or equivalent within 7 days before the first administration of study drug;
  3. Have other malignant tumors within 3 years, except for the curable basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of cervix or breast ;
  4. Non-hematologic toxicity of the previous anti-tumor treatment has not recovered to ≤ grade 1 (except for hair loss);
  5. Have uncontrollable or severe cardiovascular disease, including:

    1. Congestive heart failure with New York Heart Association (NYHA) grade II or higher, unstable angina, myocardial infarction within 6 months before first study drug administration, or arrhythmia requiring treatment during screening period, Left Ventricular Ejection Fraction (LVEF) \<50% ;
    2. Primary cardiomyopathy (such as dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, and atypical cardiomyopathy);
    3. Clinically significant QTc interval prolonged medical history, or the QTc interval of screening period > 470 ms in female, and > 450 ms in male;
    4. Uncontrollable high blood pressure (on the basis of improving life style, with 2 or more antihypertensive drugs (including diuretics) that will be reasonably tolerable and sufficient for more than one month being applied, the blood pressure has not reached to the standard yet, , or the blood pressure could only be effectively controlled by taking 4 or more antihypertensive drugs);
  6. Have medical history of deep vein thrombosis or pulmonary embolism;
  7. Have medical history of stroke or intracranial hemorrhage within 6 months before taking study drug;
  8. Have clinically significant gastrointestinal abnormalities, which might affect drug intake, transport or absorption (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.);
  9. Have serious or active infection requiring systematic anti infection treatment;
  10. At screening, patients with active uncontrolled infection [such as infection that requiring intravenous antibiotic therapy, human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, etc.]; Note: If hepatitis B virus surface antigen (HBsAg) is positive, HBV-DNA \< 1000 cop/ml, and ALT/AST≤ 2.0 × ULN can be included. HCV infection is defined as HCV-Ab positive.
  11. Have past history of or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe impairment of lung function, etc;
  12. Have history of alcohol or drug abuse;
  13. Have undergone major surgery or have not recovered from the invasive operation within 4 weeks before taking the study drug for the first time and is not suitable for the clinical trial according to the judgment of the investigators;
  14. Who is participating in other clinical studies or have participated in other intervention clinical trials within 4 weeks before screening;
  15. Pregnant or lactating women;
  16. Concomitant administration of drugs with moderate to severe inhibition or strong induction of cytochrome P450 CYP3A;
  17. Subjects determined by the investigators to be unsuitable for other reasons;
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Keynatinib treatment group

    Keynatinib, 20 mg,BID

    Drug: Keynatinib

Interventions

  • DrugKeynatinib

    All subjects shall be treated with Keynatinib twice a day (once every 12 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. It is recommended to take the drug at the same time every day. In case of missed administration, the subjects should be instructed to take it as soon as possible when they think of it on the same day. If it is within 3 hours later than the scheduled administration, the study drug should be taken as soon as possible; if the interval is \> 3 hours, skip this time and take the next dose at the normal scheduled time. Do not take double dose at one time. Every 28 days is a treatment cycle until the specified interview completed, PD, intolerable toxicity, death occurs or withdraw from the study (including withdrawal of informed consent by the subject or termination of the study when the investigator judges that the risk is greater than the benefit), whichever occurs first.

    Also known as: TL007

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (CR+PR)

    The proportion of subjects whose optimal efficacy observed from the beginning of administration is CR or PR.

    Time frame: Every 2 administration cycles in cycle 1-6 and every 3 administration cycles in cycle 7-n.

07

Study locations

3 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There is no plan to make individual participant data (IPD) available to other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Oct 2032, 144 months after the start.

Of 91 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 144 months is above that.

Counting every sponsor, half of 208 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Oct 2027 → Oct 2032 and completion Apr 2028 → Apr 2033.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2021
First posted
Mar 19, 2021
StartActual
Sep 24, 2020
Primary completionEst.
Oct 10, 2032was Oct 2027
CompletionEst.
Apr 10, 2033was Apr 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (3 China)
  • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, China
  • Peking University Third Hospital · Beijing, China
  • Fudan University Shanghai Cancer Center · Shanghai, China
Show 3 removed
  • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, China
  • Peking University Third Hospital · Beijing, China
  • Fudan University Shanghai Cancer Center · Shanghai, China
Oct 29, 2026
Primary completion
Oct 10, 2027→Oct 10, 2032
Oct 29, 2026
Study completion
Apr 10, 2028→Apr 10, 2033
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    3 sites added, 3 sites removed
    Show 3 added (3 China)
    • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, China
    • Peking University Third Hospital · Beijing, China
    • Fudan University Shanghai Cancer Center · Shanghai, China
    Show 3 removed
    • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, China
    • Peking University Third Hospital · Beijing, China
    • Fudan University Shanghai Cancer Center · Shanghai, China
    Primary completion Oct 10, 2027→Oct 10, 2032
    Study completion Apr 10, 2028→Apr 10, 2033
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04807881
Lead sponsor
Medolution Ltd.
Responsible party
Sponsor
First posted
Mar 19, 2021
Start date
Sep 24, 2020
Primary completion
Oct 10, 2032 (estimated)
Completion
Apr 10, 2033 (estimated)
Last update
Oct 29, 2026

Study contacts

Jin Yan, MD
Contact
jin.yan@teligene.com
+8618652596381
Dawei Zhang, phD
study director · Medolution Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion